{"url_path":"/sec/xtnt/8-k/2026-05-13/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 ****Other","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1453593/0001493152-26-022600-index.html","accession_number":"0001493152-26-022600","cik":"0001453593","ticker":"XTNT","issuer_name":"Xtant Medical Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1453593/0001493152-26-022600-index.html","primary_entity_key":"0001453593","primary_entity_name":"Xtant Medical Holdings, Inc."},"word_count":486,"has_tables":true,"body_markdown":"**Item\n8.01****Other\nEvents.**\n\n** **\n\nOn\nMay 13, 2026, the Company announced August 7, 2026 as the date of the Company’s 2026 Annual Meeting of Stockholders (the “2026\nAnnual Meeting”). The exact time and location of the 2026 Annual Meeting will be specified in the Company’s proxy statement\nfor the 2026 Annual Meeting, which it anticipates will be printed on or about June 11, 2026 and sent or made available to stockholders\ncommencing on or about June 12, 2026.\n\n \n\nSince\nthe date of the Company’s 2026 Annual Meeting has changed by more than 30 days from the date of last year’s Annual Meeting\nof Stockholders, stockholders who, in accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange\nAct”), wish to present proposals for inclusion in the proxy materials relating to the 2026 Annual Meeting must submit their proposals\nso that they are received by the Company at its principal executive offices no later than the close of business on May 23, 2026, which\nthe Company believes is a reasonable time before it prints and mails its proxy materials. The proposals must satisfy the requirements\nof the proxy rules promulgated by the Securities and Exchange Commission (the “SEC”) and as the rules of the SEC make clear,\nsimply submitting a proposal does not guarantee that it will be included.\n\n \n\nThe\nCompany’s Third Amended and Restated Bylaws (the “Bylaws”) provide for an advance notice procedure with regard to nominations\nof persons for election to the Board of Directors and stockholder proposals to be brought before an annual meeting. Pursuant to the terms\nof the Bylaws, any other stockholder proposals, including director nominations, to be presented at the 2026 Annual Meeting (other than\na matter brought pursuant to SEC Rule 14a-8) are required to be given in writing to the Company’s Corporate Secretary and delivered\nto or mailed and received by the Company no later than the close of business on May 23, 2026, the 10th day following the date of this\nCurrent Report on Form 8-K announcing the date of the 2026 Annual Meeting, and must contain information specified in the Bylaws.\n\n \n\nIn\naddition, if applicable, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees\nat the 2026 Annual Meeting must comply with the “universal proxy rules,” Rule 14a-19 promulgated under the Exchange Act,\nas required by and in addition to the Bylaws, including providing written notice on a timely basis no later than June 9, 2026, which\nis 60 days prior the date of the 2026 Annual Meeting, and providing certain information required by Rule 14a-19 under the Exchange Act\n(including a statement that such stockholder intends to solicit the holders of shares representing at least 67% of the voting power of\nthe Company’s shares entitled to vote on the election of directors in support of director nominees other than the Company’s\nnominees) to the Company."}